1. Home
  2. NAMS vs IREN Comparison

NAMS vs IREN Comparison

Compare NAMS & IREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • IREN
  • Stock Information
  • Founded
  • NAMS 2019
  • IREN 2018
  • Country
  • NAMS Netherlands
  • IREN Australia
  • Employees
  • NAMS N/A
  • IREN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • IREN EDP Services
  • Sector
  • NAMS Health Care
  • IREN Technology
  • Exchange
  • NAMS Nasdaq
  • IREN Nasdaq
  • Market Cap
  • NAMS 2.5B
  • IREN 2.5B
  • IPO Year
  • NAMS N/A
  • IREN 2021
  • Fundamental
  • Price
  • NAMS $19.85
  • IREN $16.93
  • Analyst Decision
  • NAMS Strong Buy
  • IREN Strong Buy
  • Analyst Count
  • NAMS 8
  • IREN 11
  • Target Price
  • NAMS $42.88
  • IREN $19.20
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • IREN 25.7M
  • Earning Date
  • NAMS 08-06-2025
  • IREN 08-27-2025
  • Dividend Yield
  • NAMS N/A
  • IREN N/A
  • EPS Growth
  • NAMS N/A
  • IREN N/A
  • EPS
  • NAMS N/A
  • IREN N/A
  • Revenue
  • NAMS $47,140,000.00
  • IREN $377,821,000.00
  • Revenue This Year
  • NAMS N/A
  • IREN $167.49
  • Revenue Next Year
  • NAMS N/A
  • IREN $79.42
  • P/E Ratio
  • NAMS N/A
  • IREN N/A
  • Revenue Growth
  • NAMS 586.97
  • IREN 128.24
  • 52 Week Low
  • NAMS $14.06
  • IREN $5.13
  • 52 Week High
  • NAMS $27.29
  • IREN $18.54
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 52.90
  • IREN 88.45
  • Support Level
  • NAMS $17.97
  • IREN $13.99
  • Resistance Level
  • NAMS $19.13
  • IREN $16.23
  • Average True Range (ATR)
  • NAMS 1.04
  • IREN 1.11
  • MACD
  • NAMS -0.03
  • IREN 0.57
  • Stochastic Oscillator
  • NAMS 35.63
  • IREN 86.14

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About IREN Iris Energy Limited

IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.

Share on Social Networks: